A Study to Assess the Effect of SB 659032 on Platelet Function
Status:
Completed
Trial end date:
2004-11-01
Target enrollment:
Participant gender:
Summary
This will be an open-label, single dose, single period study. Approximately 14 subjects will
receive one dose of 250 mg of non-enteric coated SB-659032 following a low-fat breakfast.
This study will evaluate whether SB-659032 has an effect on platelet function as determined
by platelet aggregation tests using the agonists ADP and collagen. Blood samples for PK
analysis and measurement of Lp-PLA2 activity will also be collected